Search

Your search keyword '"Tatagiba, Marcos"' showing total 1,762 results
Start Over Author "Tatagiba, Marcos"
1,762 results on '"Tatagiba, Marcos"'

3. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.

Author

Wang, Justin Z, Patil, Vikas, Liu, Jeff, Dogan, Helin, Tabatabai, Ghazaleh, Yefet, Leeor S, Behling, Felix, Hoffman, Elgin, Bunda, Severa, Yakubov, Rebecca, Kaloti, Ramneet, Brandner, Sebastian, Gao, Andrew, Cohen-Gadol, Aaron, Barnholtz-Sloan, Jill, Skardelly, Marco, Tatagiba, Marcos, Raleigh, David R, Sahm, Felix, Boutros, Paul C, Aldape, Kenneth, International Consortium on Meningiomas (ICOM), Nassiri, Farshad, and Zadeh, Gelareh

Subjects
International Consortium on Meningiomas, Humans, Meningioma, Meningeal Neoplasms, Sequence Deletion, Homozygote, Genes, p16, Cyclin-Dependent Kinase Inhibitor p16, DNA Copy Number Variations, Transcriptome, CDK inhibitor, CDKN2A, Copy number alterations, Meningiomas, Multiomic, Retinoblastoma, Cancer, Human Genome, Genetics, Brain Disorders, Biotechnology, Clinical Sciences, Neurosciences, Neurology & Neurosurgery
Abstract

Homozygous deletion of CDKN2A/B was recently incorporated into the World Health Organization classification for grade 3 meningiomas. While this marker is overall rare in meningiomas, its relationship to other CDKN2A alterations on a transcriptomic, epigenomic, and copy number level has not yet been determined. We therefore utilized multidimensional molecular data of 1577 meningioma samples from 6 independent cohorts enriched for clinically aggressive meningiomas to comprehensively interrogate the spectrum of CDKN2A alterations through DNA methylation, copy number variation, transcriptomics, and proteomics using an integrated molecular approach. Homozygous CDKN2A/B deletions were identified in only 7.1% of cases but were associated with significantly poorer outcomes compared to tumors without these deletions. Heterozygous CDKN2A/B deletions were identified in 2.6% of cases and had similarly poor outcomes as those with homozygous deletions. Among tumors with intact CDKN2A/B (without a homozygous or heterozygous deletion), we found a distinct difference in outcome based on mRNA expression of CDKN2A, with meningiomas that had elevated mRNA expression (CDKN2Ahigh) having a significantly shorter time to recurrence. The expression of CDKN2A was independently prognostic after accounting for copy number loss and consistently increased with WHO grade and more aggressive molecular and methylation groups irrespective of cohort. Despite the discordant and mutually exclusive status of the CDKN2A gene in these groups, both CDKN2Ahigh meningiomas and meningiomas with CDKN2A deletions were enriched for similar cell cycle pathways but at different checkpoints. High mRNA expression of CDKN2A was also associated with gene hypermethylation, Rb-deficiency, and lack of response to CDK inhibition. p16 immunohistochemistry could not reliably differentiate between meningiomas with and without CDKN2A deletions but appeared to correlate better with mRNA expression. These findings support the role of CDKN2A mRNA expression as a biomarker of clinically aggressive meningiomas with potential therapeutic implications.

Published
2023

7. Skull Base Meningiomas

Author

Westphal, Manfred, Saladino, Andrea, Tatagiba, Marcos, Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Steinlein, Ortrud, Series Editor, Xiao, Junjie, Series Editor, Zadeh, Gelareh, editor, Goldbrunner, Roland, editor, Krischek, Boris, editor, and Nassiri, Farshad, editor

Published
2023
Full Text
View/download PDF

16. Correction: Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas

Author

Wang, Justin Z., Patil, Vikas, Liu, Jeff, Dogan, Helin, Tabatabai, Ghazaleh, Yefet, Leeor S., Behling, Felix, Hoffman, Elgin, Bunda, Severa, Yakubov, Rebecca, Kaloti, Ramneet, Brandner, Sebastian, Gao, Andrew, Cohen-Gadol, Aaron, Barnholtz-Sloan, Jill, Skardelly, Marco, Tatagiba, Marcos, Raleigh, David R., Sahm, Felix, Boutros, Paul C., Aldape, Kenneth, Nassiri, Farshad, and Zadeh, Gelareh

Published
2023
Full Text
View/download PDF

17. Endoscopic endonasal pituitary surgery: How we do it. Consensus statement on behalf of the EANS skull base section

Author

Bove, Ilaria, Solari, Domenico, Bruneau, Michaël, Berhouma, Moncef, Jouanneau, Emmanuel, Cornelius, Jan Frederick, Messerer, Mahmoud, Daniel, Roy Thomas, Froelich, Sebastien, Mazzatenta, Diego, Meling, Torstein, Paraskevopoulos, Dimitrios, Roche, Pierre-Hugues, Schoeder, Henry W.S., Zazpe, Idoya, Visocchi, Massimiliano, Kasper, Ekkehard, Tatagiba, Marcos, and Cavallo, Luigi Maria

Published
2023
Full Text
View/download PDF

18. Differences in intraoperative sampling during meningioma surgery regarding CNS invasion – Results of a survey on behalf of the EANS skull base section

Author

Behling, Felix, Bruneau, Michaël, Honegger, Jürgen, Berhouma, Moncef, Jouanneau, Emmanuel, Cavallo, Luigi, Cornelius, Jan Frederick, Messerer, Mahmoud, Daniel, Roy Thomas, Froelich, Sébastien, Mazzatenta, Diego, Meling, Torstein, Paraskevopoulos, Dimitrios, Roche, Pierre-Hugues, Schroeder, Henry W.S., Zazpe, Idoya, Voormolen, Eduard, Visocchi, Massimiliano, Kasper, Ekkehard, Schittenhelm, Jens, and Tatagiba, Marcos

Published
2023
Full Text
View/download PDF

20. neuroGPT-X: toward a clinic-ready large language model

Author

Guo, Edward, primary, Gupta, Mehul, additional, Sinha, Sarthak, additional, Rössler, Karl, additional, Tatagiba, Marcos, additional, Akagami, Ryojo, additional, Al-Mefty, Ossama, additional, Sugiyama, Taku, additional, Stieg, Philip E., additional, Pickett, Gwynedd E., additional, de Lotbiniere-Bassett, Madeleine, additional, Singh, Rahul, additional, Lama, Sanju, additional, and Sutherland, Garnette R., additional

Published
2024
Full Text
View/download PDF

25. Management of non-vestibular schwannomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section Part II: Trigeminal and facial nerve schwannomas (CN V, VII)

Author

Bal, Jarnail, Bruneau, Michael, Berhouma, Moncef, Cornelius, Jan F., Cavallo, Luigi M., Daniel, Roy T., Froelich, Sebastien, Jouanneau, Emmanuel, Meling, Torstein R., Messerer, Mahmoud, Roche, Pierre-Hugues, Schroeder, Henry W. S., Tatagiba, Marcos, Zazpe, Idoya, and Paraskevopoulos, Dimitrios

Published
2022
Full Text
View/download PDF

28. Management of non-vestibular schwannomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section Part III: Lower cranial nerve schwannomas, jugular foramen (CN IX, X, XI) and hypoglossal schwannoma (XII)

Author

Bal, Jarnail, Bruneau, Michael, Berhouma, Moncef, Cornelius, Jan F., Cavallo, Luigi M., Daniel, Roy T., Froelich, Sebastien, Jouanneau, Emmanuel, Meling, Torstein R., Messerer, Mahmoud, Roche, Pierre-Hugues, Schroeder, Henry, Tatagiba, Marcos, Zazpe, Idoya, and Paraskevopoulos, Dimitrios

Published
2022
Full Text
View/download PDF

29. Management of non-vestibular schwannomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section. Part I: oculomotor and other rare non-vestibular schwannomas (I, II, III, IV, VI)

Author

Bal, Jarnail, Bruneau, Michael, Berhouma, Moncef, Cornelius, Jan F., Cavallo, Luigi M., Daniel, Roy T., Froelich, Sebastien, Jouanneau, Emmanuel, Meling, Torstein R., Messerer, Mahmoud, Roche, Pierre-Hugues, Schroeder, Henry W. S., Tatagiba, Marcos, Zazpe, Idoya, and Paraskevopoulos, Dimitrios

Published
2022
Full Text
View/download PDF

30. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* [S]

Author

Shraibman, Bracha, Barnea, Eilon, Kadosh, Dganit Melamed, Haimovich, Yael, Slobodin, Gleb, Rosner, Itzhak, López-Larrea, Carlos, Hilf, Norbert, Kuttruff, Sabrina, Song, Colette, Britten, Cedrik, Castle, John, Kreiter, Sebastian, Frenzel, Katrin, Tatagiba, Marcos, Tabatabai, Ghazaleh, Dietrich, Pierre-Yves, Dutoit, Valérie, Wick, Wolfgang, Platten, Michael, Winkler, Frank, von Deimling, Andreas, Kroep, Judith, Sahuquillo, Juan, Martinez-Ricarte, Francisco, Rodon, Jordi, Lassen, Ulrik, Ottensmeier, Christian, van der Burg, Sjoerd H, Thor Straten, Per, Poulsen, Hans Skovgaard, Ponsati, Berta, Okada, Hideho, Rammensee, Hans-Georg, Sahin, Ugur, Singh, Harpreet, and Admon, Arie

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Research, Rare Diseases, Brain Disorders, Neurosciences, Brain Cancer, Cancer, Good Health and Well Being, Alleles, Antigens, Neoplasm, Biomarkers, Tumor, Brain Neoplasms, Glioblastoma, Histocompatibility Antigens Class I, Humans, Peptides, Proteome, CTA, Cancer Biomarker(s), Cancer Therapeutics, HLA, Immunoaffinity, Immunotherapy, MHC, Peptidomics, Plasma or Serum Analysis, Biochemistry & Molecular Biology
Abstract

Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. Further, early detection of GBM, such as by a routine blood test, may improve survival, even with the current treatment modalities. This study includes large-scale analyses of the HLA peptidome (immunopeptidome) of the plasma-soluble HLA molecules (sHLA) of 142 plasma samples, and the membranal HLA of GBM tumors of 10 of these patients' tumor samples. Tumor samples were fresh-frozen immediately after surgery and the plasma samples were collected before, and at multiple visits after surgery. In total, this HLA peptidome analysis involved 52 different HLA allotypes and resulted in the identification of more than 35,000 different HLA peptides. Strong correlations were observed in the signal intensities and in the repertoires of identified peptides between the tumors and plasma-soluble HLA peptidomes of the individual patients, whereas low correlations were observed between these HLA peptidomes and the tumors' proteomes. HLA peptides derived from Cancer/Testis Antigens (CTAs) were selected based on their presence among the HLA peptidomes of the patients and absence of expression of their source genes from any healthy and essential human tissues, except from immune-privileged sites. Additionally, peptides were selected as potential biomarkers if their levels in the plasma-sHLA peptidome were significantly reduced after the removal of tumor mass. The CTAs identified among the analyzed HLA peptidomes provide new opportunities for personalized immunotherapy and for early diagnosis of GBM.

Published
2019

31. Imaging and diagnostic advances for intracranial meningiomas.

Author

Huang, Raymond Y, Bi, Wenya Linda, Griffith, Brent, Kaufmann, Timothy J, la Fougère, Christian, Schmidt, Nils Ole, Tonn, Jöerg C, Vogelbaum, Michael A, Wen, Patrick Y, Aldape, Kenneth, Nassiri, Farshad, Zadeh, Gelareh, Dunn, Ian F, Au, Karolyn, Barnhartz-Sloan, Jill, Brastianos, Priscilla K, Butowski, Nicholas, Carlotti, Carlos, Cusimano, Michael D, DiMeco, Francesco, Drummond, Katharine, Galanis, Evanthia, Giannini, Caterina, Goldbrunner, Roland, Hashizume, Rintaro, Hanemann, C Oliver, Herold-Mende, Christel, Horbinski, Craig, James, David, Jenkinson, Michael D, Jungk, Christine, Kaufman, Timothy J, Krischek, Boris, Lachance, Daniel, Lafougère, Christian, Lee, Ian, Liu, Jeff C, Mamatjan, Yasin, Mansouri, Alireza, Mawrin, Christian, McDermott, Michael, Munoz, David, Noushmehr, Houtan, Ng, Ho-Keung, Perry, Arie, Pirouzmand, Farhad, Poisson, Laila M, Pollo, Bianca, Raleigh, David, Sahm, Felix, Saladino, Andrea, Santarius, Thomas, Schichor, Christian, Schultz, David, Schmidt, Nils O, Selman, Warren, Sloan, Andrew, Spears, Julian, Snyder, James, Suppiah, Suganth, Tabatabai, Ghazaleh, Tatagiba, Marcos, Tirapelli, Daniela, Tonn, Joerg C, Tsang, Derek, Deimling, Andreas von, Walbert, Tobias, Westphal, Manfred, and Workewych, Adriana M

Subjects
Rare Diseases, Neurosciences, Brain Disorders, Biomedical Imaging, Cancer, Brain Cancer, Humans, Meningeal Neoplasms, Meningioma, Multimodal Imaging, Neuroimaging, International Consortium on Meningiomas, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

The archetypal imaging characteristics of meningiomas are among the most stereotypic of all central nervous system (CNS) tumors. In the era of plain film and ventriculography, imaging was only performed if a mass was suspected, and their results were more suggestive than definitive. Following more than a century of technological development, we can now rely on imaging to non-invasively diagnose meningioma with great confidence and precisely delineate the locations of these tumors relative to their surrounding structures to inform treatment planning. Asymptomatic meningiomas may be identified and their growth monitored over time; moreover, imaging routinely serves as an essential tool to survey tumor burden at various stages during the course of treatment, thereby providing guidance on their effectiveness or the need for further intervention. Modern radiological techniques are expanding the power of imaging from tumor detection and monitoring to include extraction of biologic information from advanced analysis of radiological parameters. These contemporary approaches have led to promising attempts to predict tumor grade and, in turn, contribute prognostic data. In this supplement article, we review important current and future aspects of imaging in the diagnosis and management of meningioma, including conventional and advanced imaging techniques using CT, MRI, and nuclear medicine.

Published
2019

32. Molecular and translational advances in meningiomas

Author

Suppiah, Suganth, Nassiri, Farshad, Bi, Wenya Linda, Dunn, Ian F, Hanemann, Clemens Oliver, Horbinski, Craig M, Hashizume, Rintaro, James, Charles David, Mawrin, Christian, Noushmehr, Houtan, Perry, Arie, Sahm, Felix, Sloan, Andrew, Von Deimling, Andreas, Wen, Patrick Y, Aldape, Kenneth, Zadeh, Gelareh, Au, Karolyn, Barnhartz-Sloan, Jill, Brastianos, Priscilla K, Butowski, Nicholas, Carlotti, Carlos, Cusimano, Michael D, DiMeco, Francesco, Drummond, Katharine, Galanis, Evanthia, Giannini, Caterina, Goldbrunner, Roland, Griffith, Brent, Hanemann, C Oliver, Herold-Mende, Christel, Horbinski, Craig, Huang, Raymond Y, James, David, Jenkinson, Michael D, Jungk, Christine, Kaufman, Timothy J, Krischek, Boris, Lachance, Daniel, Lafougère, Christian, Lee, Ian, Liu, Jeff C, Mamatjan, Yasin, Mansouri, Alireza, McDermott, Michael, Munoz, David, Ng, Ho-Keung, Pirouzmand, Farhad, Poisson, Laila M, Pollo, Bianca, Raleigh, David, Saladino, Andrea, Santarius, Thomas, Schichor, Christian, Schultz, David, Schmidt, Nils O, Selman, Warren, Spears, Julian, Snyder, James, Tabatabai, Ghazaleh, Tatagiba, Marcos, Tirapelli, Daniela, Tonn, Joerg C, Tsang, Derek, Vogelbaum, Michael A, Deimling, Andreas von, Walbert, Tobias, Westphal, Manfred, and Workewych, Adriana M

Subjects
Brain Cancer, Cancer, Brain Disorders, Rare Diseases, Human Genome, Genetics, Combined Modality Therapy, Genomics, Humans, Meningeal Neoplasms, Meningioma, Molecular Targeted Therapy, Prognosis, Translational Research, Biomedical, biomolecular, cell lines, epigenetic, genetic, sporadic meningioma, xenograft, International Consortium on Meningiomas, Neurosciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment options are not available in part due to limited historical biological analysis and clinical trial investigation on meningiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.

Published
2019

33. Advances in multidisciplinary therapy for meningiomas.

Author

Brastianos, Priscilla K, Galanis, Evanthia, Butowski, Nicholas, Chan, Jason W, Dunn, Ian F, Goldbrunner, Roland, Herold-Mende, Christel, Ippen, Franziska M, Mawrin, Christian, McDermott, Michael W, Sloan, Andrew, Snyder, James, Tabatabai, Ghazaleh, Tatagiba, Marcos, Tonn, Joerg C, Wen, Patrick Y, Aldape, Kenneth, Nassiri, Farshad, Zadeh, Gelareh, Jenkinson, Michael D, Raleigh, David R, and International Consortium on Meningiomas

Subjects
International Consortium on Meningiomas, Humans, Meningioma, Meningeal Neoplasms, Antineoplastic Agents, Prognosis, Combined Modality Therapy, Cranial Irradiation, Radiosurgery, Cancer, Patient Safety, Brain Disorders, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, clinical trial, meningioma, radiation, surgery, targeted therapy, Neurosciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence primarily stemming from retrospective, single-institution reports. Two of the first cooperative group studies (RTOG 0539 and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.

Published
2019

38. Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section

Author

Ng, Sam, Messerer, Mahmoud, Engelhardt, Julien, Bruneau, Michaël, Cornelius, Jan Frederick, Cavallo, Luigi Maria, Cossu, Giulia, Froelich, Sebastien, Meling, Torstein R., Paraskevopoulos, Dimitrios, Schroeder, Henry W. S., Tatagiba, Marcos, Zazpe, Idoya, Berhouma, Moncef, Daniel, Roy T., Laws, Edward R., Knosp, Engelbert, Buchfelder, Michael, Dufour, Henri, Gaillard, Stéphane, Jacquesson, Timothée, and Jouanneau, Emmanuel

Published
2021
Full Text
View/download PDF

39. Olfactory Groove Meningiomas: Comprehensive assessment between the different microsurgical transcranial approaches and the Endoscopic Endonasal Approaches, systematic review and metanalysis on behalf of the EANS skull base section

Author

Roa Montes de Oca, Juan Carlos, Gonçalves Estella, Jesús María, Nieto-Librero, Ana Belén, Galindo-Villardón, Purificación, Roa Ramírez, Carlos Julio, Gonçalves Sánchez, Jaime, Berhouma, Moncef, Cornelius, Jan Frederick, Daniel, Roy Thomas, Zazpe, Idoya, Froelich, Sébastien, Jouanneau, Emmanuel, Mazzatenta, Diego, Messerer, Mahmoud, Meling, Torstein, Paraskevopoulos, Dimitrios, Roche, Pierre-Hugues, Schroeder, Henry Werner Siegfried, Tatagiba, Marcos, Visocchi, Massimilliano, Voormolen, Eduard, Ekkehard, Kasper, and Bruneau, Michaël

Published
2022
Full Text
View/download PDF

40. Update in Cushing disease: What the neurosurgeon has to KNOW, on behalf of the EANS skull base section

Author

Eulate-Beramendi, Sayoa, Casajús, Ainhoa, Ollero, Lola, Niemann, Lynnette K., Fernández-Miranda, Juan Carlos, Bruneau, Michaël, Berhouma, Moncef, Cavallo, Luigi Maria, Cornelius, Jan Frederick, Daniel, Roy T., Froelich, Sebastien, Jouanneau, Emmanuel, Kasper, Ekkehard, Mazzatenta, Diego, Meling, Torstein R., Messerer, Mahmoud, Schroeder, Henry W.S., Tatagiba, Marcos, Visocchi, Massimiliano, Voormolen, Eduard H., and Zazpe, Idoya

Published
2022
Full Text
View/download PDF

41. Management of cavernous sinus meningiomas: Consensus statement on behalf of the EANS skull base section

Author

Corniola, Marco V., Roche, Pierre-Hugues, Bruneau, Michaël, Cavallo, Luigi M., Daniel, Roy T., Messerer, Mahmoud, Froelich, Sebastien, Gardner, Paul A., Gentili, Fred, Kawase, Takeshi, Paraskevopoulos, Dimitrios, Régis, Jean, Schroeder, Henry W.S., Schwartz, Theodore H., Sindou, Marc, Cornelius, Jan F., Tatagiba, Marcos, and Meling, Torstein R.

Published
2022
Full Text
View/download PDF

45. App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine - (TRACE)

Author

Dörner, Lorenz, primary, Grosse, Lucia, additional, Stange, Felix, additional, Hille, Hanni, additional, Kurz, Sylvia, additional, Becker, Hannes, additional, Volkmer, Sebastian, additional, Hippler, Melina, additional, Rieger, David, additional, Bombach, Paula, additional, Rieger, Johannes, additional, Weinert, Lina, additional, Svensson, Laura, additional, Anders, Carolin, additional, Cekin, Sila, additional, Paulsen, Frank, additional, Öner, Öznur, additional, Ruhm, Kristina, additional, Malek, Holly Sundberg, additional, Möller, Yvonne, additional, Tatagiba, Marcos, additional, Wallwiener, Markus, additional, Eckert, Nils, additional, Escher, Pascal, additional, Pfeifer, Nico, additional, Forschner, Andrea, additional, Bauer, Armin, additional, Zips, Daniel, additional, Bitzer, Michael, additional, Malek, Nisar, additional, Gani, Cihan, additional, Tabatabai, Ghazaleh, additional, and Renovanz, Mirjam, additional

Published
2024
Full Text
View/download PDF

46. Age, preoperative tumor volume and widening of the internal acoustic meatus are independent factors associated with poor preoperative hearing in vestibular schwannoma patients – results of a single-center retrospective analysis

Author

Dörner, Lorenz, primary, Suhm, Elisa-Maria, additional, Ries, Vanessa, additional, Goncalves, Vitor, additional, Skardelly, Marco, additional, Schittenhelm, Jens, additional, Tatagiba, Marcos, additional, and Behling, Felix, additional

Published
2023
Full Text
View/download PDF

49. NCOG-32. THE SPECIFIC PSYCHOSOCIAL BURDEN OF CAREGIVERS OF ADULT NEURO-ONCOLOGICAL PATIENTS - A PROSPECTIVE STUDY

Author

Spieker, Mareike, primary, Rapp, Marion, additional, Goebel, Simone, additional, Karger, André, additional, Rieger, David, additional, Grosse, Lucia, additional, Bombach, Paula, additional, Kurz, Sylvia, additional, Hippler, Melina, additional, Tatagiba, Marcos, additional, Sabel, Michael, additional, Tabatabai, Ghazaleh, additional, and Renovanz, Mirjam, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results